|
|
Other links at Articles > Business of Medicine |
| 1. |
Galvus Gets Positive EU Opinion
|
|
|
Galvus (vildagliptin; Novartis), a dipeptidyl peptidase-IV (DPP-IV) inhibitor that improves cell responsiveness to glucose, has received a positive opinion from European health authorities after the firm made changes to prescribing recommendations due to liver safety concerns. Reuters Health Information
|
|
|